ModDetect™

 Resource Hub

Whether you’re just discovering ModDetect or have already integrated it into your workflow, this hub brings together everything you need: application notes, protocols, publications, and support materials. From foundational guidance to in-depth insights, it’s your go-to source for trusted, up-to-date information.

Methods

Methods

Posters

ModDetect™: A Universal Antibody-Based Approach for Oligonucleotide Detection

This introductory poster presents ModDetect, Rockland’s platform of validated monoclonal antibodies that recognize key chemical modifications in oligonucleotide therapeutics (ONTs), including phosphorothioate (PS), 2’-O-methoxy-ethyl (MOE), and 2’-O-methyl (OMe). Designed for use across diverse assay types, ModDetect provides an orthogonal alternative to LC-MS/MS and ligand binding assays by enabling direct localization and quantification of ONTs in lysates and biofluids. Explore how this powerful tool supports drug development pipelines by improving analytical confidence in ADMET and regulatory studies.

POSTERS

ModDetect™: A Universal Antibody-Based Approach for Oligonucleotide Detection

This introductory poster presents ModDetect, Rockland’s platform of validated monoclonal antibodies that recognize key chemical modifications in oligonucleotide therapeutics (ONTs), including phosphorothioate (PS), 2’-O-methoxy-ethyl (MOE), and 2’-O-methyl (OMe). Designed for use across diverse assay types, ModDetect provides an orthogonal alternative to LC-MS/MS and ligand binding assays by enabling direct localization and quantification of ONTs in lysates and biofluids. Explore how this powerful tool supports drug development pipelines by improving analytical confidence in ADMET and regulatory studies.

Immunoassays for ONTs: Localization, Quantification, and Trafficking Across Systems  

This poster presents a comprehensive application of ModDetect antibodies across a range of immunoassays, highlighting their versatility in localizing, quantifying, and tracking oligonucleotide therapeutics (ONTs) in serum, cells, and tissues. Using panels specific for PS, 2'-O-methyl (OMe), and 2'-O-methoxy-ethyl (MOE) modifications, the study demonstrates effective ONT detection in ELISA, immunofluorescence, and IHC formats. Key data include quantification from HeLa lysates, co-localization with Cy5-labeled ONTs and endosomal markers, and visualization of drug biodistribution in mouse liver tissue. This marks the first ModDetect poster to explore MOE-specific data in depth, underscoring its utility for preclinical and regulatory workflows through orthogonal detection strategies. 

  Immunoassays for ONTs: Localization, Quantification, and Trafficking Across Systems

This poster presents a comprehensive application of ModDetect antibodies across a range of immunoassays, highlighting their versatility in localizing, quantifying, and tracking oligonucleotide therapeutics (ONTs) in serum, cells, and tissues. Using panels specific for PS, 2'-O-methyl (OMe), and 2'-O-methoxy-ethyl (MOE) modifications, the study demonstrates effective ONT detection in ELISA, immunofluorescence, and IHC formats. 

Key data include quantification from HeLa lysates, co-localization with Cy5-labeled ONTs and endosomal markers, and visualization of drug biodistribution in mouse liver tissue. This marks the first ModDetect poster to explore MOE-specific data in depth, underscoring its utility for preclinical and regulatory workflows through orthogonal detection strategies.

ModDetect in Action: Analytical Applications for ONT Development

After introducing the core capabilities of ModDetect, this poster showcases the next step: applying the platform in quantitative, regulatory-relevant workflows. Here, we present an ELISA-based assay optimized for detecting phosphorothioate (PS)-modified oligonucleotides in complex biological samples, including serum, blood, and tissue homogenates. This sensitive and high-throughput approach addresses key challenges outlined in FDA guidance—enabling robust ADMET and DMPK assessments critical to the clinical advancement of ONTs. With potential extensions into Biolayer Interferometry (BLI) and immunoprecipitation, this work positions ModDetect as a powerful tool for therapeutic monitoring and mechanistic insight.    

ModDetect in Action: Analytical Applications for ONT Development

After introducing the core capabilities of ModDetect, this poster showcases the next step: applying the platform in quantitative, regulatory-relevant workflows. Here, we present an ELISA-based assay optimized for detecting phosphorothioate (PS)-modified oligonucleotides in complex biological samples, including serum, blood, and tissue homogenates.

This sensitive and high-throughput approach addresses key challenges outlined in FDA guidance—enabling robust ADMET and DMPK assessments critical to the clinical advancement of ONTs. With potential extensions into Biolayer Interferometry (BLI) and immunoprecipitation, this work positions ModDetect as a powerful tool for therapeutic monitoring and mechanistic insight.

Manuscript

Manuscript

Bioanalytical Assays for Oligonucleotide Therapeutics

Since their discovery in 1978, nucleic acid therapies—including oligonucleotide therapeutics (ONTs) and vaccines—have grown rapidly, especially following the approval of the first mRNA COVID-19 vaccine in 2021. Now considered the third major drug class after small molecules and antibodies, ONTs like ASOs and siRNAs regulate gene expression by targeting RNA.

However, challenges such as instability, poor uptake, off-target effects, and immunogenicity hinder their development. Regulatory agencies, including the FDA, stress the need for improved analytical tools. We propose that immunoassays using highly specific anti-ONT antibodies offer a promising solution.

Protocols

  ELISA Protocol

  IF Protocol

  IHC Protocol

Manuscript

Manuscript

 Bioanalytical Assays for Oligonucleotide Therapeutics

Since their discovery in 1978, nucleic acid therapies—including oligonucleotide therapeutics (ONTs) and vaccines—have grown rapidly, especially following the approval of the first mRNA COVID-19 vaccine in 2021. Now considered the third major drug class after small molecules and antibodies, ONTs like ASOs and siRNAs regulate gene expression by targeting RNA.

However, challenges such as instability, poor uptake, off-target effects, and immunogenicity hinder their development. Regulatory agencies, including the FDA, stress the need for improved analytical tools. We propose that immunoassays using highly specific anti-ONT antibodies offer a promising solution.

Flyers

Publications

Chimento, D. P., Anderson, A. L., Fial, I., & Ascoli, C. A. (2025). Bioanalytical assays for oligonucleotide therapeutics: Adding Antibody-Based immunoassays to the toolbox as an orthogonal approach to LC-MS/MS and ligand binding assays. Nucleic Acid Therapeutics, 35(1), 6–15.

Fial, I., Farrier, S. A., Chimento, D. P., Ascoli, C. A., Wan, X., & Oliver, P. L. (2025). Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2′-O-Methoxyethyl Modifications for Intracellular Trafficking and Biodistribution Studies. Nucleic Acid Therapeutics, 35(4).

Disha Kashyap, Martina Cadeddu, Peter L. Oliver, Thomas A. Milne, and Michael J. Booth. Harnessing BET-Bromodomain Assisted Nuclear Import for Targeted Subcellular Localization and Enhanced Efficacy of Antisense Oligonucleotides. Journal of the American Chemical Society.

  Interested in our ModDetect™ product line?

We can help move your program forward—contact us to find out how.